Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome

Quaglino, Pietro; Fava, Paolo; Pileri, Alessandro; Grandi, Vieri; Sanlorenzo, Martina; Panasiti, Vincenzo; Guglielmo, Alba; Alberti‐Violetti, Silvia; Novelli, Mauro; Astrua, Chiara; Rubatto, Marco; Tonella, Luca; Berti, Emilio; Pimpinelli, Nicola; Abate, Simona Osella; Fierro, Maria Teresa; Vermeer, Maarten H.; Scarisbrick, Julia; Ribero, Simone

doi:10.1016/j.jid.2020.07.026

Cited by 31 publications

(34 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Contrarily to solid tumors, nonsolid tumors such as mycosis fungoides and adult T-cell leukemia/lymphoma [ 33 , 34 , 35 , 36 ] showed that high expression of CADM1 had an unfavorable clinical behavior [ 17 , 29 , 37 ]. In nonsolid tumors, CADM1 contributes to the invasion of the tumor into vessels and other organs, suggesting that the prognostic significance of CADM1 is different in the types of tumors.…”

Section: Discussionmentioning

confidence: 99%

Cell Adhesion Molecule 1 (CADM1) Is an Independent Prognostic Factor in Patients with Cutaneous Squamous Cell Carcinoma

et al. 2021

View full text Add to dashboard Cite

Cell adhesion molecular 1 (CADM1) is a multifunctional cell adhesion molecule belonging to the immunoglobulin superfamily, which suppresses malignant solid tumor development. However, the correlation between CADM1 expression and prognosis in cutaneous squamous cell carcinoma (cSCC) patients remains unclear. In a retrospective analysis of 88 patients diagnosed with cSCC at our institution between January 2006 and December 2016, the degree of CADM1 expression in tumor cells was evaluated by immunostaining. Fifty-five and 33 patients had tumors with high and low CADM1 expression, respectively. Low CADM1 expression on the tumor was associated with poor differentiation, whereas the Kaplan–Meier curve and log-lank test indicated a favorable prognosis with high CADM1 expression. Multivariate analysis excluding the effect of the degree of differentiation and clinical stages showed that the hazard ratio (HR) of survival was significantly increased with low CADM1 expression. Thus, CADM1 expression is an independent prognostic factor for cSCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Cell Adhesion Molecule 1 (CADM1) Is an Independent Prognostic Factor in Patients with Cutaneous Squamous Cell Carcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Hence, throughout the years, antibodies targeting PD-1 and CTLA-4 have been developed for treating several tumors, with the aim of restoring PD-1+ T-cell function and eventually halting tumor proliferation (79). In the growing field of immuno-oncology, studies have been carried out in order to achieve a thorough understanding of PD-1 and CTLA-4 expression in cutaneous lymphomas as well (80). The results have been diverse and noteworthy.…”

Section: The Pd-1/pdl-1 Axis In Primary Cutaneous Lymphomamentioning

confidence: 99%

Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives

et al. 2021

Self Cite

View full text Add to dashboard Cite

Primary cutaneous T-cell lymphomas (PCTCL) are the most common types of cutaneous lymphomas, with Mycosis fungoides as the most frequent subtype. Besides early stages which usually have a good prognosis, advanced stages remain a great therapeutic challenge with low survival rates. To date, none of the currently available therapeutic options have significantly improved the outcomes of advanced cutaneous lymphomas. Recent studies have demonstrated that immune-checkpoint molecules, such as PD-1 and CTLA-4, play part in the proliferation pathways of neoplastic T-cells, as well as in other tumors. Hence, the potential role of immune-checkpoint-inhibitors in treating cutaneous lymphomas has been investigated in the last years. Herein, we outline the current knowledge regarding the role of immune-checkpoint molecules in PCTCL, their signaling pathways, microenvironment and therapeutic inhibition rationale. Moreover, we review the published data on immunotherapies in PCTCL and summarize the currently ongoing clinical trials in this field.

show abstract

“…

…”

mentioning

confidence: 99%

“…[1][2][3] Research into the tumor microenvironment, microbiome, and molecular genetics may yield further information as we strive to develop MF/SS therapy from the bench to the bedside. 3 Although progress has been made on multiple fronts in MF, some important-particularly epidemiologic and clinical-questions remain unanswered.Racial disparities are well known to exist in CTCLs, particularly MF and SS. [4][5][6][7] The incidence of MF and SS in the United States is higher in African American/Black patients than in White patients 4 ; in addition, MF has an earlier age at onset in Black patients compared with White patients.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Mycosis Fungoides in Black Patients: Time for a Better Look

Myskowski¹

2021

Cutis

View full text Add to dashboard Cite

ecent advances in the immunopathogenesis and therapy of cutaneous T-cell lymphoma (CTCL) have shown great promise for the care of patients with mycosis fungoides (MF) and Sézary syndrome (SS). [1][2][3] Research into the tumor microenvironment, microbiome, and molecular genetics may yield further information as we strive to develop MF/SS therapy from the bench to the bedside. 3 Although progress has been made on multiple fronts in MF, some important-particularly epidemiologic and clinical-questions remain unanswered.Racial disparities are well known to exist in CTCLs, particularly MF and SS. [4][5][6][7] The incidence of MF and SS in the United States is higher in African American/Black patients than in White patients 4 ; in addition, MF has an earlier age at onset in Black patients compared with White patients. 4,5 Gender disparities also exist, with relatively more Black females than males affected with MF [4][5][6] ; in particular, early-onset MF (ie, <40 years of age) is more common in Black females than Black males. 6,7 According to Surveillance, Epidemiology, and End Results (SEER) data 4 and the US National Cancer Database, 5 African American/Black patients with MF have worse outcomes compared with other races (shorter overall survival and higher mortality) and also exhibit higher stages of disease at presentation (stage IIb or higher). 5 Black race also was found to be a predictor of poor overall survival after accounting for disease characteristics, socioeconomic factors, and types of treatment. The factors responsible for these racial disparities remain unclear.A fortuitous collision of interests and technology may have helped to shed light on some of the reasons for these racial disparities in MF. Nearly 2 decades ago, high-quality, whole-body digital cutaneous photography was implemented by the Dermatology Service at

show abstract

Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome

Cited by 31 publications

References 126 publications

Cell Adhesion Molecule 1 (CADM1) Is an Independent Prognostic Factor in Patients with Cutaneous Squamous Cell Carcinoma

Cell Adhesion Molecule 1 (CADM1) Is an Independent Prognostic Factor in Patients with Cutaneous Squamous Cell Carcinoma

Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives

Mycosis Fungoides in Black Patients: Time for a Better Look

Contact Info

Product

Resources

About